Bicycle Therapeutics plc

UK-based clinical-stage oncology company developing Bicycle Toxin Conjugates (BTCs), a proprietary class of bicyclic peptide-drug conjugates engineered to combine antibody-like affinity with small-molecule tumor penetration and rapid renal clearance. Lead asset zelenectide pevedotin (BT8009) is a Nectin-4 BTC in Phase 2/3 development for metastatic urothelial cancer, with BT5528 (EphA2) and a Genentech-partnered immuno-oncology collaboration behind it.